REH

human lymphoblastic leukemia cell line (non-T, non-B), derived from ALL patient

Cell Type:
PBMC
Tissue Origin:
blood
Species:
human
Research Area:
Cancer Research/Cell Biology
Immunotherapy / Hematology
Cell Characteristics:
Suspension

Recommended Media

RPMI-1640 medium was developed by Moore et al., at Roswell Park Memorial Institute, hence the acronym RPMI. The formulation is based on the RPMI-1630 series of media utilizing a bicarbonate buffering system and alterations in the amounts of amino acids and vitamins. RPMI-1640 medium has been used for the culture of human normal and neoplastic leukocytes. RPMI-1640 when properly supplemented, has demonstrated wide applicability for supporting growth of many types of cell cultures, including fresh human lymphocytes in the 72-hour phytohemagglutinin (PHA) stimulation assay.

There are a variety of formulations:
12-702         - with L-glutamine
BE12-702/U1 - with UltraGlutamineI
BE15-702D    - [powder] with L-glutamine
12-167          - without L-glutamine
12-115          - with L-glutamine and 25 mM HEPES buffer
BE12-115/U1 - with UltraGlutamineI and 25 mM HEPES buffer
04-525          - with L-glutamine and 165 nM MOPS (used for some mycological assays)
09-774          - with L-glutamine, 25 mM HEPES buffer 100 units/ml penicillin, 50 ug/ml streptomycin
12-918          - without L-glutamine or phenol red
BE12-752       - with L-glutamine, without D-glucose

Storage = 2ºC to 8ºC 
  (versions without L-glutamine and those with UltraGlutamine can be stored at 15ºC to 30ºC)

Transfection Information

Lonza Optimized Protocol
Optimization Guideline
Filter:
The table below shows data for the cell type and Nucleofector™ Platform selected. Those data are either based on Lonza Optimized Protocols or on results shared from customers who performed an optimization based on our guidelines. In case no data are shown for the selected Nucleofector™ Platform, please take a look at our optimization strategy to get further guidance on how to easily determine optimal Nucleofection conditions yourself.
Protocol Kit Program Cells Efficiency Viable Cells Substrate Format Platform
R G-009 5e6 30% 70% Plasmid (general) 2 µg 100 µl I/II/2b
R O-009 5e6 47% 50% Plasmid (general) 2 µg 100 µl I/II/2b
R O-013 2e6 67% 90% Plasmid (general) 2 µg 100 µl I/II/2b
R I-009 4e6 68% 50% Plasmid (general) 2 µg 100 µl I/II/2b
R G-009 4e6 55% 69% Plasmid (general) 2 µg 100 µl I/II/2b
SF CA-137 2e5 71-75% 63-67% Plasmid (general) 1 µg 20 µl 4D X-Unit
SF CA-137 1e6 82-86% 57-67% Plasmid (general) 5 µg 100 µl 4D X-Unit

Citations

Categories:
Transfection 
Authors:
Pottier N, Cheok MH, Yang W, Assem M, Tracey L, Obenauer JC, Panetta JC, Relling MV, Evans WE 
In:
Hum Mol Genet (2007) 16(19): 2261-71 
Categories:
Transfection 
Authors:
Leclerc GJ, Leclerc GM, Kinser TT, Barredo JC 
In:
BMC Cancer (2006) 6: 132 
Categories:
Transfection 
Authors:
Lahne HU, Kloster MM, Lefdal S, Blomhoff HK, Naderi S 
In:
Oncogene (2006) 25(17): 2468-76